Became President and CEO of Novavax in April of 2011. The stock price at the time was in the $40 range.
In the almost 12 years occupying these positions to the day of his retirement, Stan has made many decisions towards the goal of building a great company that delivered solid long term returns to shareholders who put their faith in his leadership.
Stan walks into retired with the stock trading around $10. So regardless whether investors agreed or disagreed over the years in the direction Stan led Novavax, the bottom line is that his tenure resulted in shareholders losing approx 75% of their investment. You include opportunity cost and there is no way to say that Stan's tenure at Novavax was anything but a total and complete failure.